Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Moodys
Colorcon
McKinsey
Harvard Business School

Last Updated: February 3, 2023

CLINICAL TRIALS PROFILE FOR IBUPROFEN AND FAMOTIDINE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Ibuprofen And Famotidine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00450216 ↗ Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment Completed Horizon Pharma Ireland, Ltd., Dublin Ireland Phase 3 2007-03-01 The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen.
NCT00450658 ↗ Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers Completed Horizon Pharma Ireland, Ltd., Dublin Ireland Phase 3 2007-03-01 The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen.
NCT00613106 ↗ Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216) Completed Horizon Pharma Ireland, Ltd., Dublin Ireland Phase 3 2007-09-01 The purpose of this study is to evaluate the safety of long-term treatment with HZT-501.
NCT00984815 ↗ Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment Completed Horizon Pharma Ireland, Ltd., Dublin Ireland Phase 3 2009-09-01 The purpose of this study is to evaluate the safety of long-term treatment with HZT-501, a fixed-dose combination oral tablet of 800 mg ibuprofen and 26.6 mg famotidine for patients that require long-term NSAID treatment.
NCT01563185 ↗ Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis Completed Pediatric Rheumatology Collaborative Study Group Phase 4 2012-04-01 The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24 weeks. The secondary objectives are to evaluate the PK characteristics of DUEXIS in JIA patients and to evaluate the signs and symptoms of JIA in patients aged 10 years to 16 years, 11 months receiving DUEXIS for up to 24 weeks.
NCT01563185 ↗ Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis Completed Horizon Pharma Ireland, Ltd., Dublin Ireland Phase 4 2012-04-01 The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24 weeks. The secondary objectives are to evaluate the PK characteristics of DUEXIS in JIA patients and to evaluate the signs and symptoms of JIA in patients aged 10 years to 16 years, 11 months receiving DUEXIS for up to 24 weeks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ibuprofen And Famotidine

Condition Name

Condition Name for Ibuprofen And Famotidine
Intervention Trials
Chronic Low Back Pain 2
Chronic Regional Pain Syndrome 2
Chronic Soft Tissue Pain 2
Osteoarthritis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ibuprofen And Famotidine
Intervention Trials
Arthritis 2
Osteoarthritis 2
Nociceptive Pain 2
Low Back Pain 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ibuprofen And Famotidine

Trials by Country

Trials by Country for Ibuprofen And Famotidine
Location Trials
United States 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ibuprofen And Famotidine
Location Trials
Texas 2
Pennsylvania 2
Massachusetts 1
Louisiana 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ibuprofen And Famotidine

Clinical Trial Phase

Clinical Trial Phase for Ibuprofen And Famotidine
Clinical Trial Phase Trials
Phase 4 2
Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ibuprofen And Famotidine
Clinical Trial Phase Trials
Completed 5
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ibuprofen And Famotidine

Sponsor Name

Sponsor Name for Ibuprofen And Famotidine
Sponsor Trials
Horizon Pharma Ireland, Ltd., Dublin Ireland 5
Pediatric Rheumatology Collaborative Study Group 1
Duke University 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ibuprofen And Famotidine
Sponsor Trials
Industry 5
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
AstraZeneca
Baxter
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.